Business Context and Reporting Period
Oragenics, Inc. filed a Form 8-K on September 7, 2006, reporting the entry into a material definitive agreement involving the approval of stock option grants to directors, executive officers, and an independent contractor.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on equity compensation terms.
- Option Exercise Price: $0.74 per share (based on AMEX closing price on the grant date).
- Total Options Granted: 315,000 shares.
Material Changes and Grant Details
The Board of Directors and Compensation Committee approved the following grants on September 7, 2006:
| Recipient | Role | Number of Options | Vesting Schedule |
|---|---|---|---|
| David Gury | Director and Audit Committee Chair | 75,000 | Vests September 8, 2006 |
| George Hawes | Director and Audit Committee Member | 65,000 | Vests September 8, 2006 |
| Robert Zahradnik | President/CEO | 75,000 | 3-year vesting period |
| Jeffrey Hillman | Chief Scientific Officer | 75,000 | 3-year vesting period |
| Joann Zahradnik | Independent Consultant | 25,000 | 3-year vesting period |
Grants to non-employee directors were made in lieu of cash fees for future meeting attendance. Grants to executives and the consultant were approved as incentives for services.
Guidance, Outlook, and Risks
The filing text does not provide financial guidance, outlook, management commentary on operations, or specific risk factors beyond the standard disclosure of the equity grant agreement.
Investor Verification Checklist
- Verify the total number of outstanding shares to assess potential dilution from the 315,000 new options.
- Confirm the current market price of Oragenics common stock relative to the $0.74 exercise price.
- Review the company's most recent 10-K or 10-Q for cash flow status, as this 8-K does not report liquidity or debt levels.
- Check the specific vesting conditions and performance metrics (if any) attached to the 3-year vesting grants for executives.